Phio Pharmaceuticals (PHIO) Stock Forecast, Price & News

Phio Pharmaceuticals (NASDAQ:PHIO) Frequently Asked Questions

Is Phio Pharmaceuticals a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Phio Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Phio Pharmaceuticals stock.
View analyst ratings for Phio Pharmaceuticals or view top-rated stocks.

Are investors shorting Phio Pharmaceuticals?

Phio Pharmaceuticals saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 238,100 shares, a drop of 78.7% from the April 15th total of 1,120,000 shares. Based on an average daily volume of 3,340,000 shares, the short-interest ratio is presently 0.1 days. Approximately 1.8% of the shares of the stock are short sold.
View Phio Pharmaceuticals' Short Interest.

When is Phio Pharmaceuticals' next earnings date?

Phio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Phio Pharmaceuticals.

How were Phio Pharmaceuticals' earnings last quarter?

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) released its earnings results on Friday, May, 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.11.
View Phio Pharmaceuticals' earnings history.

What price target have analysts set for PHIO?

1 brokerages have issued 1-year price objectives for Phio Pharmaceuticals' stock. Their forecasts range from $6.00 to $6.00. On average, they expect Phio Pharmaceuticals' stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 748.1% from the stock's current price.
View analysts' price targets for Phio Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Phio Pharmaceuticals' key executives?

Phio Pharmaceuticals' management team includes the following people:

• Dr. Gerrit Dispersyn Dr. Med. Sc, Ph.D., Pres, CEO & Director (Age 47, Pay $583.14k)
• Ms. Caitlin Kontulis, VP of Fin. & Admin. and Sec. (Age 36)

Who are some of Phio Pharmaceuticals' key competitors?

Some companies that are related to Phio Pharmaceuticals include Forward Pharma A/S (FWP), vTv Therapeutics (VTVT), Terns Pharmaceuticals (TERN), Elite Pharmaceuticals (ELTP), Newron Pharmaceuticals (NWPHF), Zynerba Pharmaceuticals (ZYNE), Bioxytran (BIXT), Aptorum Group (APM), Eledon Pharmaceuticals (ELDN), Synthetic Biologics (SYN), Galecto (GLTO), FSD Pharma (HUGE), Moleculin Biotech (MBRX), Acerus Pharmaceuticals (ASPCF) and Aileron Therapeutics (ALRN).
View all of PHIO's competitors.

What other stocks do shareholders of Phio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phio Pharmaceuticals investors own include DURECT (DRRX), CymaBay Therapeutics (CBAY), Ocugen (OCGN), Akero Therapeutics (AKRO), Ampio Pharmaceuticals (AMPE), Boxlight (BOXL), Evofem Biosciences (EVFM), Fulcrum Therapeutics (FULC), Jaguar Health (JAGX) and Milestone Pharmaceuticals (MIST).

What is Phio Pharmaceuticals' stock symbol?

Phio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHIO."

Who are Phio Pharmaceuticals' major shareholders?

Phio Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.23%), Cetera Investment Advisers (0.66%), Renaissance Technologies LLC (0.30%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Phio Pharmaceuticals stock include Gerrit Dispersyn and Robert L Ferrara.
View institutional ownership trends for Phio Pharmaceuticals.

Which institutional investors are buying Phio Pharmaceuticals stock?

PHIO stock was acquired by a variety of institutional investors in the last quarter, including Cetera Investment Advisers, Renaissance Technologies LLC, and Vanguard Group Inc.. Company insiders that have bought Phio Pharmaceuticals stock in the last two years include Gerrit Dispersyn, and Robert L Ferrara.
View insider buying and selling activity for Phio Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Phio Pharmaceuticals?

Shares of PHIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Phio Pharmaceuticals' stock price today?

One share of PHIO stock can currently be purchased for approximately $0.71.

How much money does Phio Pharmaceuticals make?

Phio Pharmaceuticals has a market capitalization of $9.66 million and generates $20 thousand in revenue each year. The company earns $-13.29 million in net income (profit) each year or ($0.920010) on an earnings per share basis.

How many employees does Phio Pharmaceuticals have?

Phio Pharmaceuticals employs 12 workers across the globe.

What is Phio Pharmaceuticals' official website?

The official website for Phio Pharmaceuticals is phiopharma.com.

How can I contact Phio Pharmaceuticals?

Phio Pharmaceuticals' mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The company can be reached via phone at (508) 767-3861, via email at [email protected], or via fax at 508-767-3862.